查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2158758

PCSK9標靶藥物市場：全球市場預測，2026-2032年

PCSK9 Targeted Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，PCSK9 標靶藥物市場將成長至 171.2 億美元，複合年成長率為 9.53%。

主要市場統計數據
基準年 2025 90.5億美元
預計年份：2026年 99.2億美元
預測年份 2032 171.2億美元
複合年成長率 (%) 9.53%

PCSK9標靶藥物：概述

對於除生活型態介入和傳統降血脂療法外，還需要額外治療以降低低密度脂蛋白膽固醇（LDL-C）的患者，PCSK9標靶療法是一種成熟的治療選擇。此類療法包括單株抗體和其他旨在降低PCSK9活性或表現的療法，從而促進肝臟清除血液中的LDL-C。臨床應用取決於心血管風險評估、治療指引、過去治療史、用藥遵從性、給藥要求和用藥條件。

治療格局正朝著早期風險管理轉變。

隨著人們越來越關注高LDL-C的累積暴露以及持續降低風險的必要性，治療方法正朝著更個人化的血脂管理方向發展。對於遺傳性高膽固醇症、已確診動脈粥狀硬化性心血管疾病或對其他治療反應不佳或不耐受的患者，PCSK9標靶治療方案正被更頻繁地探索。注射頻率、治療連續性、監測、預先核准以及與基層基層醫療和專科醫生的協作等實際因素，與藥物療效同等重要，共同決定著臨床應用。

透過人工智慧（AI）加強患者識別和護理協調

人工智慧可以透過識別長期臨床記錄中持續高LDL-C水平、疑似遺傳性高膽固醇症或高心血管風險的患者，來輔助PCSK9標靶藥物的處方流程。預測工具可以幫助確定檢測優先順序、識別治療缺口、實現個人化追蹤並識別用藥依從性風險。然而，在演算法輸出影響處方或保險決策之前，臨床檢驗、透明的決策邏輯、隱私保護、偏差監測和臨床醫生監督至關重要。

區域差異反映了醫療指南、醫療服務取得途徑和醫療系統的能力。

北美擁有完善的專業醫療基礎設施，並高度重視以結果為導向的血脂管理，但經濟負擔和核准程序可能會影響醫療服務的可近性。在歐洲，成熟的心血管指引與各國在報銷制度、診斷路徑和專科醫師資源方面的差異並存。亞太地區呈現出極大的多樣性，從完善的都市區循環系統服務到農村地區醫療資源分配不均，且人們越來越關注遺傳性高膽固醇症及其預防。拉丁美洲在篩檢、經濟負擔和醫療服務的連續性方面存在差異。中東地區受益於不斷擴展的公立和私立醫療體系，但保險覆蓋範圍和專科醫生資源取得方面存在顯著差異。在非洲，診斷、檢測設施的可用性、治療的經濟負擔以及長期心血管風險管理方面都存在明顯的未滿足需求。

經濟和安全因素會影響實施條件。

在東南亞國協，由於醫保報銷系統、醫療保健成熟度和血脂專家資源的可近性存在差異，區域合作和在地化的診斷流程至關重要。金磚國家擁有大規模的患者群體、多元化的公共衛生優先事項、國內生產能力，但在獲得先進治療方面存在差異。歐盟受益於通用的科學和監管框架，但成員國在醫療技術評估和報銷體系方面仍存在差異。七國集團成員國通常擁有完善的臨床基礎設施和資料利用能力，但成本效益要求和預算管理會影響其應用。海灣合作理事會國家通常擁有資源充足的醫療保健系統，但面臨預防項目差異和依賴進口療法等挑戰。北約成員國的醫療保健系統各不相同，導致在採購、指南實施和心血管護理結構方面存在差異。

各國在診斷、保險報銷和醫療服務方面的優先事項各不相同。

澳洲和加拿大擁有完善的臨床體系，但面臨地域性醫療服務可近性方面的挑戰以及結構化的報銷決策。巴西和墨西哥都市區醫療保健水準有顯著差異，同時也面臨經濟負擔和診斷上的差異。中國和印度正在擴大心血管服務，同時也努力應對醫療能力、自付費用和專科醫生資源的區域性差異。日本、韓國、法國、德國、義大利、西班牙和英國在血脂管理方面擁有豐富的經驗，但在處方標準、診療路徑和保險報銷管理方面存在國家差異。在俄羅斯，心血管疾病負擔沉重，亟需加強預防措施和持續護理，但醫療服務可近性和醫療體系的限制阻礙了先進療法的應用。在這些國家，遺傳性高膽固醇症的篩檢、持續治療和公平取得仍然是首要任務。

行業領導者應協調證據、獲取途徑和患者支持。

行業領導者應建立證據包，將低密度高膽固醇症（LDL-C）降低與具有臨床意義的心血管結局、患者亞組、治療連續性以及醫療保健系統在真實世界實踐中的價值聯繫起來。他們還應簡化治療啟動和續期流程，加強遺傳性高膽固醇血症的診斷網路，並設計以注射指導、提醒、減輕經濟負擔和隨訪為中心的患者支持服務。與臨床醫生、保險公司、實驗室和公共衛生計畫合作可以更好地識別合適的患者並加強後續護理。實施人工智慧的組織應建立涵蓋檢驗、可解釋性、資料品質、網路安全和人為課責的管治。

調查方法。

本執行摘要系統地整合了權威的臨床指南、同行評審的證據、監管和報銷文件、醫療保健系統出版物以及公開的心血管風險管理資訊。分析按治療進展、人工智慧應用、地區、經濟集團和國家/地區具體情況進行組織。研究結果採用質性解釋，並考慮了臨床合格、診斷能力、管理、用藥依從性、經濟負擔、報銷和系統發展等因素。本摘要未使用任何市場估算、預測、市場佔有率、預估或公司特定聲明。

PCSK9標靶藥物的實施需要採取全面、公平的方法。

PCSK9標靶藥物的策略重要性不僅取決於其藥理作用，還取決於醫療系統如何有效識別合格的患者、確保治療的連續性以及管理藥物取得。協調一致的心血管疾病預防、提高遺傳性高膽固醇症（LDL-C）管理的一致性和公平性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：PCSK9標靶藥物市場：依藥物類別分類

  • 單株抗體
    • 阿利洛庫單抗
    • 埃沃洛庫姆
  • SiRNA

第8章：PCSK9標靶藥物市場：依適應症分類

  • 動脈粥狀硬化性心血管疾病
  • 雜合子遺傳性性高膽固醇症
  • 遺傳性高膽固醇症

第9章：PCSK9標靶藥物市場：依最終用戶分類

  • 診所
  • 醫院
  • 專業醫療中心

第10章：PCSK9標靶藥物市場：依分銷管道分類

  • 物理藥房
  • 網路藥房

第11章：PCSK9標靶藥物市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：PCSK9標靶藥物市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：PCSK9標靶藥物市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Akeso, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Innovent Biologics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • LIB Therapeutics, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Shanghai Junshi Biosciences Co., Ltd.
  • Silence Therapeutics PLC
  • Verve Therapeutics, Inc.

第16章 主要專家

Product Code: MRR-4654A89DBBD2

The PCSK9 Targeted Drugs Market is projected to grow by USD 17.12 billion at a CAGR of 9.53% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.05 billion
Estimated Year [2026] USD 9.92 billion
Forecast Year [2032] USD 17.12 billion
CAGR (%) 9.53%

PCSK9-Targeted Drugs: Executive Overview

PCSK9-targeted drugs represent an established approach to lowering low-density lipoprotein cholesterol (LDL-C) for patients who require additional treatment beyond lifestyle changes and conventional lipid-lowering therapy. The category includes monoclonal antibodies and other approaches designed to reduce PCSK9 activity or expression, supporting greater hepatic clearance of circulating LDL-C. Clinical use is shaped by cardiovascular-risk assessment, treatment guidelines, prior therapy, adherence, administration requirements, and access conditions.

Treatment Pathways Are Shifting Toward Earlier Risk Management

The treatment landscape is moving toward more individualized lipid management, with greater attention to cumulative exposure to elevated LDL-C and the need for sustained risk reduction. PCSK9-targeted options are increasingly considered when patients have familial hypercholesterolemia, established atherosclerotic cardiovascular disease, or inadequate response or tolerance to other therapies. Practical factors-including injection frequency, persistence, monitoring, prior authorization, and integration with primary and specialty care-are becoming as important as pharmacologic efficacy in determining real-world use.

Artificial Intelligence Strengthens Patient Identification and Care Coordination

Artificial intelligence can support PCSK9-targeted drug pathways by identifying patients with persistently elevated LDL-C, probable familial hypercholesterolemia, or high cardiovascular risk from longitudinal clinical records. Predictive tools may help prioritize testing, flag treatment gaps, personalize follow-up, and identify adherence risks. However, clinical validation, transparent decision logic, privacy safeguards, bias monitoring, and clinician oversight are essential before algorithmic outputs influence prescribing or coverage decisions.

Regional Differences Reflect Guidelines, Access, and Health-System Capacity

North America is characterized by advanced specialty-care infrastructure and strong emphasis on outcomes-based lipid management, although affordability and authorization processes can affect access. Europe combines mature cardiovascular guidelines with country-level variation in reimbursement, diagnostic pathways, and specialist capacity. Asia-Pacific presents substantial diversity, ranging from sophisticated urban cardiology services to uneven access in rural areas, with growing attention to familial hypercholesterolemia and prevention. Latin America faces differences in screening, affordability, and continuity of care. The Middle East is supported by expanding private and public healthcare capacity but varies widely in coverage and specialist access. Africa has significant unmet needs related to diagnosis, laboratory availability, treatment affordability, and long-term cardiovascular-risk management.

Economic and Security Groups Shape Adoption Conditions

ASEAN markets differ in reimbursement structures, healthcare maturity, and access to lipid specialists, making regional coordination and locally appropriate diagnostic pathways important. BRICS countries combine large patient populations with varied public-health priorities, domestic manufacturing capabilities, and uneven access to advanced therapies. The European Union benefits from shared scientific and regulatory frameworks but retains national differences in health-technology assessment and reimbursement. G7 members generally have strong clinical infrastructure and data capabilities, while cost-effectiveness requirements and budget management influence utilization. GCC countries often possess well-resourced healthcare systems but face variation in prevention programs and reliance on imported therapies. NATO members span diverse health systems, creating differences in procurement, guideline implementation, and cardiovascular-care capacity.

Country Priorities Vary Across Diagnosis, Reimbursement, and Delivery

Australia and Canada combine robust clinical systems with geographic access challenges and structured reimbursement decisions. Brazil and Mexico face substantial variation between urban and rural care, alongside affordability and diagnostic gaps. China and India are expanding cardiovascular services while managing differences in regional capacity, out-of-pocket exposure, and specialist availability. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom have established lipid-management expertise, with national differences in prescribing criteria, care pathways, and reimbursement administration. Russia's cardiovascular disease burden creates a need for stronger prevention and continuity of care, while access conditions and health-system constraints influence the deployment of advanced therapies. Across these countries, familial hypercholesterolemia detection, treatment persistence, and equitable access remain central priorities.

Industry Leaders Should Align Evidence, Access, and Patient Support

Leaders should develop evidence packages that connect LDL-C reduction with clinically meaningful cardiovascular outcomes, patient subgroups, persistence, and real-world health-system value. They should simplify initiation and renewal processes, strengthen diagnostic networks for familial hypercholesterolemia, and design patient-support services around injection training, reminders, affordability navigation, and follow-up. Partnerships with clinicians, payers, laboratories, and public-health programs can improve appropriate identification and continuity of care. Organizations deploying artificial intelligence should establish governance covering validation, explainability, data quality, cybersecurity, and human accountability.

Methodology Combines Clinical, Policy, and Health-System Evidence

This executive summary uses a structured synthesis of authoritative clinical guidance, peer-reviewed evidence, regulatory and reimbursement documentation, health-system publications, and publicly available information on cardiovascular-risk management. Analysis is organized by treatment evolution, artificial-intelligence applications, region, economic grouping, and country context. Findings are interpreted qualitatively, with attention to clinical eligibility, diagnostic capacity, administration, adherence, affordability, reimbursement, and system readiness. No market estimates, market shares, forecasts, or company-specific claims are used.

PCSK9-Targeted Drugs Require Integrated, Equity-Focused Execution

The strategic importance of PCSK9-targeted drugs depends not only on their pharmacologic role but also on how effectively health systems identify eligible patients, sustain treatment, and manage access. Progress will come from coordinated cardiovascular prevention, better familial-hypercholesterolemia detection, reliable follow-up, evidence-based reimbursement, and responsible use of digital and artificial-intelligence tools. Industry and healthcare leaders that connect clinical value with practical delivery can improve the consistency and equity of LDL-C management across diverse populations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. PCSK9 Targeted Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Monoclonal Antibody
    • 7.2.1. Alirocumab
    • 7.2.2. Evolocumab
  • 7.3. SiRNA

8. PCSK9 Targeted Drugs Market, by Indication

  • 8.1. Introduction
  • 8.2. Atherosclerotic Cardiovascular Disease
  • 8.3. Heterozygous Familial Hypercholesterolemia
  • 8.4. Homozygous Familial Hypercholesterolemia

9. PCSK9 Targeted Drugs Market, by End User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Hospitals
  • 9.4. Specialty Centers

10. PCSK9 Targeted Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Offline Pharmacy
  • 10.3. Online Pharmacy

11. PCSK9 Targeted Drugs Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. PCSK9 Targeted Drugs Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. PCSK9 Targeted Drugs Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Akeso, Inc.
  • 15.2. Alnylam Pharmaceuticals, Inc.
  • 15.3. Amgen Inc.
  • 15.4. Arrowhead Pharmaceuticals, Inc.
  • 15.5. AstraZeneca PLC
  • 15.6. Bristol-Myers Squibb Company
  • 15.7. Eli Lilly and Company
  • 15.8. F. Hoffmann-La Roche Ltd.
  • 15.9. Innovent Biologics, Inc.
  • 15.10. Ionis Pharmaceuticals, Inc.
  • 15.11. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 15.12. LIB Therapeutics, LLC
  • 15.13. Merck & Co., Inc.
  • 15.14. Novartis AG
  • 15.15. Pfizer Inc.
  • 15.16. Regeneron Pharmaceuticals, Inc.
  • 15.17. Sanofi S.A.
  • 15.18. Shanghai Junshi Biosciences Co., Ltd.
  • 15.19. Silence Therapeutics PLC
  • 15.20. Verve Therapeutics, Inc.

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global PCSK9 Targeted Drugs Market, Years Considered for the Study
  • FIGURE 2. Global PCSK9 Targeted Drugs Market, Research Design
  • FIGURE 3. Global PCSK9 Targeted Drugs Market, Research Framework
  • FIGURE 4. Global PCSK9 Targeted Drugs Market, Data Triangulation
  • FIGURE 5. Global PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global PCSK9 Targeted Drugs Market Size, by Drug Class, 2025 vs 2032 (%)
  • FIGURE 7. Global PCSK9 Targeted Drugs Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global PCSK9 Targeted Drugs Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 9. Global PCSK9 Targeted Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global PCSK9 Targeted Drugs Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 11. Global PCSK9 Targeted Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 13. Global PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global PCSK9 Targeted Drugs Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global PCSK9 Targeted Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global PCSK9 Targeted Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global PCSK9 Targeted Drugs Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global PCSK9 Targeted Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global PCSK9 Targeted Drugs Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global PCSK9 Targeted Drugs Market Segmentation & Coverage
  • TABLE 2. Global PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 4. Global Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Monoclonal Antibody Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Alirocumab Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Alirocumab Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Alirocumab Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Evolocumab Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Evolocumab Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Evolocumab Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global SiRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global SiRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global SiRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 17. Global Atherosclerotic Cardiovascular Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Atherosclerotic Cardiovascular Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Atherosclerotic Cardiovascular Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Heterozygous Familial Hypercholesterolemia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Heterozygous Familial Hypercholesterolemia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Heterozygous Familial Hypercholesterolemia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Homozygous Familial Hypercholesterolemia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Homozygous Familial Hypercholesterolemia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Homozygous Familial Hypercholesterolemia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 27. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Specialty Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Specialty Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Specialty Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 37. Global Offline Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Offline Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Offline Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Asia-Pacific PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Asia-Pacific PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 46. Asia-Pacific PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 47. Asia-Pacific PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 48. Asia-Pacific PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 49. Asia-Pacific PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 50. North America PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. North America PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 52. North America PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 53. North America PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 54. North America PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 55. North America PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 56. Latin America PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Latin America PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 58. Latin America PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 59. Latin America PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 60. Latin America PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 61. Latin America PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 62. Europe PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Europe PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 64. Europe PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 65. Europe PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 66. Europe PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 67. Europe PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 68. Middle East PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Middle East PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 70. Middle East PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 71. Middle East PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 72. Middle East PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 73. Middle East PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 74. Africa PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Africa PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 76. Africa PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 77. Africa PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 78. Africa PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 79. Africa PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 80. Global PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 81. ASEAN PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. ASEAN PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 83. ASEAN PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 84. ASEAN PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 85. ASEAN PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 86. ASEAN PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 87. GCC PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. GCC PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 89. GCC PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 90. GCC PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 91. GCC PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 92. GCC PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 93. European Union PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 94. European Union PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 95. European Union PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 96. European Union PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 97. European Union PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 98. European Union PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 99. BRICS PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 100. BRICS PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 101. BRICS PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 102. BRICS PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 103. BRICS PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 104. BRICS PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 105. G7 PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 106. G7 PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 107. G7 PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 108. G7 PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 109. G7 PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 110. G7 PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 111. NATO PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 112. NATO PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 113. NATO PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 114. NATO PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 115. NATO PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 116. NATO PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 117. Global PCSK9 Targeted Drugs Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 118. United States PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 119. United States PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 120. United States PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 121. United States PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 122. United States PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 123. United States PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 124. Canada PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 125. Canada PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 126. Canada PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 127. Canada PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 128. Canada PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 129. Canada PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 130. Mexico PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 131. Mexico PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 132. Mexico PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 133. Mexico PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 134. Mexico PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 135. Mexico PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 136. Brazil PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 137. Brazil PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 138. Brazil PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 139. Brazil PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 140. Brazil PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 141. Brazil PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 142. United Kingdom PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 143. United Kingdom PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 144. United Kingdom PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 145. United Kingdom PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 146. United Kingdom PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 147. United Kingdom PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 148. Germany PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 149. Germany PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 150. Germany PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 151. Germany PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 152. Germany PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 153. Germany PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 154. France PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 155. France PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 156. France PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 157. France PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 158. France PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 159. France PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 160. Russia PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 161. Russia PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 162. Russia PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 163. Russia PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 164. Russia PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 165. Russia PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 166. Italy PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 167. Italy PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 168. Italy PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 169. Italy PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 170. Italy PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 171. Italy PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 172. Spain PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 173. Spain PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 174. Spain PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 175. Spain PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 176. Spain PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 177. Spain PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 178. China PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 179. China PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 180. China PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 181. China PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 182. China PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 183. China PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 184. India PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 185. India PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 186. India PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 187. India PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 188. India PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 189. India PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 190. Japan PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 191. Japan PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 192. Japan PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 193. Japan PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 194. Japan PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 195. Japan PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 196. Australia PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 197. Australia PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 198. Australia PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 199. Australia PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 200. Australia PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 201. Australia PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 202. South Korea PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 203. South Korea PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 204. South Korea PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
  • TABLE 205. South Korea PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 206. South Korea PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 207. South Korea PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 208. Global PCSK9 Targeted Drugs Market Share, by Key Player, 2025
  • TABLE 209. Global PCSK9 Targeted Drugs Market, Key Experts